Lespedeza capitata extract for use in the field of hair care
Lespedeza capitata extract inhibits DKK1 and 5α-reductase to prolong the hair growth cycle and reduce sebum production, effectively treating hair loss and seborrhea, and related skin disorders.
Patent Information
- Application Number
- JP2021504400
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-07-27
- Filing Date
- 2019-07-19
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2039-07-19
AI Technical Summary
Current treatments for hair loss and scalp seborrhea, such as androgenic alopecia and scalp seborrhea, are inadequate in addressing the hormonal dysregulation and overproduction of dihydrotestosterone (DHT) and sebum, leading to premature hair cycle termination and excessive sebum secretion, respectively.
The use of Lespedeza capitata extract, particularly from its aerial parts, which inhibits the synthesis and release of Dickkopf-related protein 1 (DKK1) and 5α-reductase activity in dermal papilla cells, thereby prolonging the hair growth cycle and reducing sebum production.
The extract effectively prevents hair loss and seborrhea by promoting hair growth, increasing hair density, and reducing greasiness, while also addressing related skin disorders like scalp seborrheic dermatitis and erythema.
Smart Images

Figure 0007591492000001 
Figure 0007591492000002 
Figure 0007591492000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a compound called Lespedeza capitata (Lespedeza capitata) for use in cosmetics and / or dermatology in the hair care field, more particularly in the treatment and / or prevention of alopecia and / or seborrhea of the scalp. Lespedeza capitata Concerning the Michx. extract. [Background technology]
[0002] Lespedeza capitata (Michx.) is a perennial plant of the legume family originating from North America. Lespedeza capitata (Michx.) is cultivated in Europe, especially in France.
[0003] Lespedeza capitata Michx. is a downy plant whose erect stems can reach a height of 1.5 m. Its leaves are alternate, compound, and generally trifoliate; the leaflets are approximately 4.5 x 1.8 cm long; the petioles are short (2-5 mm). The leaves and stems are covered with hairs that may give the plant a silvery sheen. The flowers are butterfly-shaped and grow in dense axillary clusters. The petals are pink-purple as usual, but sometimes white. The calyx is persistent and becomes brownish over time. The fruit is non-dehiscent and holds a single seed. Lespedeza capitata Michx. is deep-rooted, with a taproot that can reach 2.5 m into the soil.
[0004] Lespedeza capitata Michx. is part of the traditional medicine of many Native American peoples. The Omaha-Ponca used the stems as moxa to treat rheumatism or neuralgia. The Comanches used the leaves in the form of decoctions. The Meskwaki used the roots as an antidote for poisoning (USDA-NRCS. Plant Guide 05 Dec. 2000). Today, Lespedeza capitata Michx. is primarily cultivated for its use in dietary supplements and medicinal, homeopathic and veterinary preparations.
[0005] The aerial parts of Lespedeza capitata Michx. have been extensively studied for their properties in the urinary system, especially their diuretic and azotamic capacity. Several clinical trials have been presented in the literature. The majority were carried out in the 60s-80s, mainly in France. These trials concerned in particular the intravenous administration of Lespedeza capitata Michx. extracts in patients with renal disease. The cholesterol-lowering activity of an orally administered Lespedeza capitata Michx. tincture has been presented in the literature in a clinical trial carried out in 39 subjects with stable hypercholesterolemia (Yarnell and Abascal, Alternative and Complementary Therapies. 13(1): 18-23, 2007).
[0006] The aerial parts of Lespedeza capitata Michx. are still used for their therapeutic properties. In powdered or extract form, they are marketed as dietary supplements, homeopathic or medicinal preparations (azotemia; urinary system) or veterinary preparations (urinary system) for the preparation of decoctions.
[0007] A recent publication has shown that the ethanol extract of Lespedeza capitata Michx. induces in vitro proliferation of fibroblasts and keratinocytes, inhibits collagenase and stimulates collagen synthesis by fibroblasts, and has lipolytic properties (Pastorino et al. 2017. Industrial Crops and Products. 96: 158-164). Patent application CN104606122 also claims that Lespedeza capitata in mixture with other plants can burn pregnancy-related abdominal fat. Summary of the Invention
[0008] Unexpectedly and surprisingly, the applicants have shown that Lespedeza capitata Michx. extract has targeted pharmacological activity in the field of treatment and / or prevention of skin and hair disorders, in particular for combating hair loss and for treating scalp seborrhea and related disorders.
[0009] Indeed, the inventors have shown that Lespedeza capitata Michx. extract inhibits the synthesis and release of Dickkopf-related protein 1 (DKK1) by cells of the dermal papilla, thus helping to delay and prevent hair loss and extending the hair life cycle.
[0010] Furthermore, the inventors have shown that Lespedeza capitata Michx. extract inhibits 5α-reductase activity in dermal papilla cells. As a result, Lespedeza capitata Michx. extract is also useful in the field of hair loss prevention as well as in scalp seborrhea and related skin and hair disorders.
[0011] This new use of Lespedeza capitata Michx. in the hair care field is the subject of the present invention, which makes it possible to envisage the application of various Lespedeza capitata Michx.-based products for improving the aesthetic appearance of the hair by care, as well as for preventing and / or treating hair loss and / or scalp seborrhea and all associated skin and hair disorders.
[0012] Thus, the present invention also relates to a Lespedeza capitata extract for its use for the treatment and / or prevention of at least one skin and hair disorder.
[0013] Advantageously, said skin and hair disorder is selected from alopecia, scalp seborrheic dermatitis, scalp erythema, scalp seborrhea and combinations thereof.
[0014] The skin and hair disorder may also be oily hair.
[0015] Hair care is constantly attracting attention from researchers, not only for cosmetic purposes but also to prevent hair loss and regrow hair.
[0016] The hair follicle is a small organ that is anchored in the skin down to the subcutaneous tissue and whose main function is the formation of the hair shaft. The hair follicle is a dynamic structure that produces hair. Hair does not grow continuously but follows a hair growth cycle that is divided into three phases: · Anagen: The dermal papilla cells (fibroblasts) send signals to the stem cells of the hair bulb, which allows them to multiply. These cells are transformed and form the sulfur matrix of the hair, covering the dermal papilla. They divide and differentiate into keratinocytes, the cells responsible for the structure of the hair. For the proper structure of the hair, the keratinocytes need sulfur-containing proteins, vitamin B6 and various minerals such as zinc and magnesium. The duration of this phase determines the length of the hair and depends on the proliferation and differentiation of the hair matrix cells at the base of the hair follicle. Catagen: The hair matrix cells die and, as a result, the dermal papilla no longer comes into contact with them. There is no more exchange between these cells. The hair follicle and dermal papilla migrate down to the epidermis. Telogen: The dermal papilla and hair bulb cells become fully formed and inactive. The hair falls out. A new hair grows and the cycle begins again.
[0017] Hair continually regenerates itself, with the majority of the 100,000-150,000 strands that make up a single head of hair being in the anagen phase. In healthy hair, normal periodic shedding is around 60-100 strands per day. Any loss beyond this, whether cyclical or progressive, is considered pathological.
[0018] The term alopecia describes partial or total hair loss. Many factors can contribute to alopecia, such as genetic factors, age, sex, disease, stress, hormonal problems, side effects of medications and injuries. Several forms of alopecia are distinguishable: Hereditary androgenic alopecia is the most common. Premature hair loss occurs in genetically predisposed subjects and particularly affects men. This alopecia manifests as reduced hair volume or even baldness and is seen in 50% of men over the age of 50; Postmenopausal alopecia is the most common cause of boldness in women. In women, hair loss is more diffuse and diffuse than in men. Diffuse female alopecia is a disorder that often begins at menopause and affects approximately 40% of older women over the age of 70. The term diffuse indicates that, unlike men, hair loss affects all of the hair on the scalp evenly; Acute or reactive alopecia can be associated with chemotherapy treatments, stress, childbirth, major dietary deficiencies, iron deficiency and hormonal disorders. This alopecia is a simultaneous and diffuse loss of substantial hair volume; Cicatricial alopecia can be caused by skin problems (tumors, burns, alopecia areata), acute irradiation, lupus erythematosus or parasites (tinea, lichen); · Alopecia areata appears to be of autoimmune origin and is characterized by one or more patchy lesions of various sizes; Congenital alopecia is rare and is the absence of hair follicles or abnormalities (mutations) in the hair follicles.
[0019] Alopecia is essentially related to the disruption of hair regeneration, which leads to an acceleration of cycle frequency at the expense of hair quality and then its quantity. The most common phenomenon is a shortening of the growth cycle (anagen phase) due to the cessation of cell proliferation. The result is an early induction of catagen, an increase in the number of hair follicles in the telogen phase, and therefore an increase in hair loss. Therefore, to combat alopecia, it is necessary to restart the hair cycle, for example by activating the anagen phase.
[0020] It is now known that the causative mechanism of hereditary androgenetic alopecia (also called seborrheic alopecia) involves, among other things, a hormonal component with an overexpression of androgen receptors (testosterone and DHT receptors) and a stronger activity of the 5α-reductase enzyme. This hormonal dysregulation leads to an overproduction of dihydrotestosterone (DHT), the active metabolite of testosterone. In the dermal papilla, this metabolite stimulates the production of hair cycle inhibitors, resulting in a shortening of the anagen phase, which drives the hair into the telogen phase too early and does not give the hair follicle enough time to produce good quality keratin, which inevitably leads to exhaustion after a few cycles and an exhaustion of the hair follicle's hair shaft-producing capacity.
[0021] This alopecia due to excess androgens also affects women during menopause (postmenopausal alopecia) or after androgen treatment. The alopecia begins on the sides and vertex. The alopecia is more diffuse and diffuse than in men. The alopecia involves the entire scalp evenly.
[0022] 5α-reductase inhibitors therefore make it possible to treat and / or prevent hair loss in men and / or women.
[0023] Seborrhea is the excessive production of sebum by the sebaceous glands. Overall, humans have 2 million sebaceous glands along with 6 million hairs. The distribution of sebaceous glands is not uniform. The density of sebaceous glands ranges from 300 to 900 sebaceous glands / cm on the face and scalp. 2 This density reaches 100 sebaceous glands / cm on the chest and upper back. 2 Before and after. The activity of the sebaceous glands is influenced by androgens. Androgens are active only under the influence of the 5α-reductase enzyme, which ensures the metabolism of androgens in the sebaceous glands, inducing the production of sebum. Excessive activation of the 5α-reductase enzyme induces seborrhea.
[0024] The sites of seborrhea are the medial facial areas (forehead, nose, chin) where the sebaceous glands are most numerous and largest. Seborrhea can also affect the scalp, most commonly the frontal and frontotemporal areas and the vertex of the skull.
[0025] Scalp seborrhea leads to aesthetic and dermatological conditions such as scalp seborrheic dermatitis and scalp erythema.
[0026] Seborrheic dermatitis of the scalp (SD) is characterized by diffuse pink, inflamed patches covered with oily, white, crust-like scales that adhere to the epidermis and are sometimes purulent and sometimes severely pruritic.
[0027] Seborrhea is often associated with androgenetic alopecia.
[0028] Thus, an effective inhibitor of the 5α-reductase enzyme would make it possible to reduce sebum secretion, treat seborrhea and resolve the dermatological and / or aesthetic problems associated with seborrhea.
[0029] The hair growth cycle is a highly regulated process in which the various compartments of the hair follicle (dermal papilla, stem cells present in the hair bulb, and keratinocytes in the hair follicle matrix) enter into close contact through various molecular exchanges. Among the signals involved, Wnt / β-catenin signaling is known to promote hair growth (Leiros et al., Br. J. Dermatol. 166(5)-1035-1042, 2012).
[0030] Androgenetic alopecia, the most common form of hair loss, is clearly an androgenic disorder: androgens dysregulate factors secreted by the dermal papilla, which leads to failure of stem cell differentiation by inhibition of the canonical Wnt signaling pathway.
[0031] The hair growth cycle inhibitor Dickkopf-related protein 1 (DKK1) is known to block canonical activation of the Wnt pathway mediated by β-catenin and promote catagen progression (Kwack et al., J. Invest. Dermatol. 132(6):1554-60, 2012). DKK1 has also been described to be regulated by androgens (Kwack et al., J. Invest. Dermatol. 128(2):262-9, 2008).
[0032] Taken together, these results indicate that DKK1 plays an important role in androgen-induced inhibition of hair growth and early induction of catagen in androgenetic alopecia (Inui and Itami, J. Dermatol. Sci. 61(1):1-6, 2011).
[0033] Extract according to the invention In this specification, the Lespedeza capitata Michx. plant may be referred to as Lespedeza capitata for short.
[0034] In the context of the present invention, the Lespedeza capitata extract is obtained from one or more parts of the Lespedeza capitata plant selected from the roots and aerial parts such as stems, branches, leaves, fruits, seeds and / or flowers. Advantageously, it is the aerial parts selected from the leaves, stems or flowers, respectively, alone or in mixtures.
[0035] In a particular embodiment of the invention, the extract is obtained from the leaves and / or stems and / or flowers of Lespedeza capitata, in particular from the dried matter.
[0036] In a particular embodiment of the invention, the extract is obtained from a culture of Lespedeza capitata cells.
[0037] According to a particular embodiment, this extract is a hydroalcoholic extract, in particular a hydroethanolic extract. Advantageously, it is an extract obtained from a hydroalcoholic extraction, in particular a hydroethanolic extraction.
[0038] According to a preferred embodiment, the extract according to the invention is obtainable by the method according to the invention described below.
[0039] The Lespedeza capitata plant or parts thereof may be fresh or dried, whole, cut or crushed, and then may undergo an extraction process.
[0040] The method for preparing the extract according to the present invention comprises the step of extracting all or part of the Lespedeza capitata plant with a hydrophilic to non-polar solvent, preferably a hydrophilic to medium polar aqueous solvent.
[0041] "Medium polarity solvent" refers within the meaning of the present invention to a solvent selected from the group consisting of C1-C5 alcohols, glycols (propylene glycol, butylene glycol, pentylene glycol), glycerol, acetone, alkyl esters (e.g., in particular ethyl acetate and isopropyl acetate), mixtures of water-miscible solvents, such as hydroalcoholic mixtures or acetone / water mixtures, or even hydrotropic solvents. Another group of hydrotropic solvents are amphiphilic molecules soluble in water that, from sufficient concentration, can be extracted into medium polarity compounds, such as those described in the characteristics of the extract.
[0042] Within the meaning of the present invention, "alkyl ester" refers to a R1-COO-R2 compound, where R1 and R2 are identical or different (C1-C6) alkyl groups. The ester may in particular be an acetate ester, i.e., a CH3COO-R2 compound.
[0043] Within the meaning of the present invention, a "(C1-C6) alkyl" group refers to a straight or branched hydrocarbon chain comprising 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl groups.
[0044] Within the meaning of the present invention, "non-polar solvent" denotes a solvent selected from heptane, hexane, limonene, halogenated hydrocarbons (chloroform, dichloromethane), supercritical CO2 and a mixture of supercritical CO2 + ethanol.
[0045] It is understood that the choice of a non-polar solvent as defined above for the extraction is not preferred.
[0046] "Hydrophilic solvent" means a solvent selected from the group consisting of water, subcritical water, water-miscible alcohols (eg, ethanol), C3-C5 glycols, glycerol, acetone, and mixtures thereof.
[0047] "Aqueous solvent" refers to a solvent selected from the group consisting of water alone and water in combination with subcritical water, water-miscible alcohols (e.g., ethanol), C3-C5 glycols, glycerol, acetone, and mixtures thereof.
[0048] Within the meaning of the present invention, a "dry extract" refers to an extract that does not contain the extracting or carrier solvent or that only contains the solvent in negligible traces. Such a dry extract therefore contains only material derived from Lespedeza capitata. It may also contain negligible traces of the extracting solvent.
[0049] In a preferred embodiment of the invention, the extraction solvent may be selected from ethyl acetate, isopropyl acetate, C1-C5 alcohols, C3-C5 glycols, glycerol or water or mixtures thereof. Preferably, it is water or a water / alcohol mixture. Advantageously, it is an ethanol / water mixture.
[0050] Even more advantageously, this ethanol / water mixture is characterized in that the ethanol / water ratio is between 9:1 and 7:3 (v / v).
[0051] Even more advantageously, the medium polar solvent is an ethanol / water mixture in the ratio 9:1 (v / v).
[0052] According to another particular embodiment of the invention, the extraction is carried out under reflux, with stirring or statically, at ambient temperature or at a temperature between ambient and reflux. The extraction may be assisted by ultrasound, microwave or extrusion with a plant weight / solvent volume ratio of 1 / 3 to 1 / 30 for a time period ranging from 1 minute to 48 hours. The extraction may be repeated 2 to 3 times.
[0053] According to another particular embodiment of the invention, the solid phase is then separated by centrifugation or filtration in order to recover a particle-free, clear liquid phase. Filtration can be carried out on filter papers or filtration plates with a cut-off threshold between 5 and 20 μm, in particular between 10 and 20 μm. Suitable filter papers or filtration plates can be selected from the Pall® series K line of depth filtration products. Such plates consist of a balanced mixture of cellulose fibers, diatomaceous earth and perlite, which allows the creation of a well-defined matrix. Thus, for example, Pall® K300 to K900 series k plates can be selected. The liquid phase corresponding to the extract can be more or less concentrated to such an extent that a dry extract is obtained.
[0054] In another embodiment of the invention, a carrier can be added during the concentration step to obtain an extract containing 1-75% dry extract. The carrier can be maltodextrin, lactose, silica, glycerin, glycol or any other cosmetically acceptable carrier that solubilizes the extract, preferably of biological origin, such as biological glycols (1,2-pentanediol; 1,3-butanediol; 1,3-propanediol, etc.), and also hydrotropes, such as alkyl glycosides (Sepiclear, Apyclean, APXC4, etc.).
[0055] According to a particular embodiment of the invention, the extract may be decolorized, for example with activated charcoal, to remove all or part of the chlorophyll.
[0056] According to a particular embodiment of the invention, the Lespedeza capitata extract according to the invention is characterized by a content of total polyphenols (% by weight relative to the weight of the dry extract) of 2 to 40%, in particular 5 to 35%, more particularly 10 to 30% and even more particularly approximately 25%, expressed in grams of epicatechin per 100 grams of dry extract.
[0057] In the present invention, "approximately" means that the value concerned may be 10%, in particular 5%, especially 1% lower or higher than the indicated value.
[0058] Compositions according to the invention Another subject of the present invention relates to a cosmetic, dermatological or skin and hair composition intended for the care of the hair and / or scalp, comprising at least one Lespedeza capitata extract according to the invention and at least one cosmetically or dermatologically acceptable excipient.
[0059] In the present invention, "cosmetically or dermatologically acceptable" means generally safe, non-toxic, not biologically or otherwise undesirable, and useful in the preparation of cosmetic, dermatological or skin and hair compounds that are acceptable for cosmetic, dermatological or skin and hair use, particularly by topical application to the hair and / or scalp.
[0060] By "topical application" is meant application to the skin, in particular the scalp, mucous membranes and / or the integuments, in particular the hair and scalp.
[0061] By "integument" is meant hair and body hair, eyebrows, eyelashes and / or nails, preferably head hair.
[0062] In a particular embodiment of the invention, the composition according to the invention is characterised in that it is present in a form suitable for topical administration to the scalp and / or hair.
[0063] In a particular embodiment of the invention, the compositions according to the invention are intended for topical application, in particular by application of the composition to the scalp and / or hair and integument.
[0064] Thus, the compositions according to the invention can be present in the forms generally known for topical administration, namely in particular lotions, balms, shampoos, mousses, gels, dispersions, emulsions, sprays, serums, masks or creams, comprising excipients that allow for penetration to improve the properties and accessibility of the active ingredients.
[0065] Advantageously, the compositions according to the invention may be in the forms generally known for topical administration to the hair and scalp, namely in particular shampoos, conditioners, hair creams, hair lotions, masks or no-rinse sprays, and therefore they are cosmetic, dermatological or skin and hair compositions.
[0066] Thus, a distinction is made between products that are formulated to be rinsed and those that do not require rinsing.
[0067] In a particular embodiment of the invention, the composition according to the invention is characterized in that it is in a form suitable for oral administration. It has been shown in practice that Lespedeza capitata is able to inhibit the renin-angiotensin converting enzyme even when administered orally (Yarnell, 2012, IJKD, vol 6, 407-418). Thus, this extract is not completely metabolized during its passage through the digestive tract.
[0068] According to another embodiment of the present invention, the composition according to the present invention can also be in the form generally known for oral administration, namely, in particular, tablets, capsules, powders, granules and oral solutions or suspensions.When the solid composition is prepared in the form of tablets, the main active ingredient is mixed with pharmaceutical carriers such as gelatin, starch, lactose, magnesium stearate, talc, gum arabic, etc.The tablets can be coated with sucrose or other suitable materials, or even treated so that they have a prolonged or delayed activity and release a predetermined amount of active ingredient in a sustained manner.
[0069] Capsule formulations are obtained by mixing the active ingredient with a diluent and pouring the resulting mixture into hard or soft capsules.
[0070] In addition to the extracts according to the invention, these compositions contain a physiologically acceptable medium, generally water or a solvent system, such as an alcohol, ether or glycol. They may also contain surfactants, complexing agents, preservatives, stabilizers, emulsifiers, thickeners, gelling agents, moisturizers, emollients, trace elements, essential oils, fragrances, dyes, moisturizers or thermal waters.
[0071] In one embodiment, the cosmetic or dermatological composition according to the invention, in particular the skin and hair composition, comprises from 0.0001 to 2% by weight, preferably from 0.001 to 1% by weight, preferably from 0.005 to 0.8% by weight, more preferably from 0.01 to 0.5% by weight of Lespedeza capitata extract, by weight of dry extract relative to the total weight of the composition.
[0072] The Lespedeza capitata extract used in the composition according to the invention advantageously comprises a dry extract content ranging from 1 to 10% by weight, preferably from 1 to 5% by weight, relative to the total weight of the extract.
[0073] In a particular embodiment, the Lespedeza capitata extract is the only active agent used in a composition intended for hair and / or scalp care, by which is meant a curative or preventive agent for the skin and hair disorders to which the present invention is directed.
[0074] The extract according to the invention or the cosmetic or dermatological composition according to the invention can also be used in combination with treatments for alopecia, such as finasteride or minoxidil, and / or in combination with compounds useful for good hair structure, such as, for example, sulfur-containing proteins, vitamin B6 and various minerals, such as zinc and / or magnesium.
[0075] The extract or composition according to the invention may also be combined with at least one antibacterial agent, antifungal agent, anti-inflammatory agent and mixtures thereof.
[0076] The extract according to the invention or the cosmetic or dermatological composition according to the invention can be used on individuals with micrografts.
[0077] Preferably, the compositions according to the invention have a light texture that also allows optimal penetration without making the hair or scalp sticky. From the first application, the hair regains strength and vitality.
[0078] The present invention therefore also relates to a dermatological composition according to the invention for use for the treatment and / or prevention of at least one skin and hair disorder.
[0079] The composition according to the invention for use for the treatment and / or prevention of at least one skin and hair disorder, characterized in that the at least one skin and hair disorder is selected from alopecia, scalp seborrheic dermatitis, scalp erythema, scalp seborrhea and combinations thereof.
[0080] The composition according to the invention for the treatment and / or prevention of at least one skin and hair disorder is characterized in that the alopecia is selected from the group consisting of androgenetic alopecia, reactive alopecia, postmenopausal alopecia and alopecia areata.
[0081] Another object of the present invention relates to a dermatological composition comprising a Lespedeza capitata extract according to the invention for use in the prevention and / or treatment of alopecia.
[0082] In certain embodiments of the invention, the alopecia is selected from the group consisting of androgenetic alopecia, postmenopausal alopecia, reactive alopecia and alopecia areata.
[0083] According to another aspect, the present invention relates to the cosmetic use of an extract according to the invention according to the method described above or a cosmetic or dermatological composition according to the invention according to the method described above for the care of the hair and / or the scalp in order to limit hair loss and / or to promote hair growth and / or to increase the density of the hair follicles and / or to obtain a higher coverage of the hair and / or to promote hair follicle regeneration and / or to reduce scalp seborrhea and / or to make the hair less greasy.
[0084] In another aspect, the present invention relates to a method for the cosmetic treatment of hair and / or scalp comprising the administration to a person in need thereof of an extract according to the invention to limit hair loss and / or promote hair growth and / or increase the density of hair follicles and / or obtain higher coverage of hair and / or promote hair follicle regeneration and / or reduce scalp seborrhea and / or make hair less greasy, which administration may be topical or oral.
[0085] Thus, the present invention relates to the cosmetic use of the Lespedeza capitata extract according to the invention for limiting hair loss and / or promoting hair growth and / or increasing the density of hair follicles and / or obtaining higher hair coverage and / or promoting hair follicle regeneration and / or reducing scalp seborrhea and / or making hair less greasy.
[0086] Alternatively, the present invention relates to the cosmetic use of a cosmetic composition according to the invention for the care of the hair and / or scalp, in order to limit hair loss and / or to promote hair growth and / or to increase the density of hair follicles and / or to obtain higher coverage of hair and / or to promote hair follicle regeneration and / or to reduce scalp seborrhea and / or to make the hair less greasy.
[0087] The present invention also relates to a cosmetic method comprising the administration to an individual in need thereof of an effective amount of an extract according to the invention according to the above method or a cosmetic or dermatological composition according to the invention according to the above method, for the care of the hair and / or scalp in order to limit hair loss and / or to promote hair growth and / or to increase the density of the hair follicles and / or to obtain a higher coverage of the hair and / or to promote hair follicle regeneration and / or to reduce scalp seborrhea.
[0088] In another aspect, the present invention relates to a cosmetic treatment comprising the administration to a person in need thereof of a cosmetic composition according to the present invention to the hair and / or scalp to limit hair loss and / or promote hair growth and / or increase hair follicle density and / or obtain higher hair coverage and / or promote hair follicle regeneration and / or reduce scalp seborrhea and / or make hair less greasy, said administration being preferably topical to the hair and / or scalp.
[0089] The extract or the cosmetic or dermatological composition according to the invention is advantageously administered topically and / or orally.
[0090] The compositions according to the invention, such as those described herein, are characterised in that they are present in a form suitable for topical administration to the scalp and / or hair.
[0091] The compositions according to the invention, such as those described herein, are characterized in that they are in a form suitable for oral administration.
[0092] The extract according to the invention, or the cosmetic or dermatological composition according to the invention, also helps to stop hair loss by lengthening the hair cycle so as to preserve the hair capital in quantity and quality.
[0093] According to another aspect, the invention also relates to a cosmetic hair care method intended to improve the aesthetics of the hair by promoting hair growth and / or by promoting the production of hair with greater coverage and / or by limiting hair loss, characterized in that it comprises the application to the hair and / or the scalp of an effective amount of a lespedeza extract according to the invention, or of a composition according to the invention, of the hair and / or the scalp, leaving said composition in contact with the hair and / or the scalp and, optionally, rinsing the hair and the scalp.
[0094] According to another aspect, the invention also relates to a cosmetic hair care method intended to improve the aesthetics of hair by combating oily hair and / or restoring shine to dull hair and / or cleansing a greasy scalp, characterized in that it comprises applying to the hair and / or scalp an effective amount of a lespedeza extract according to the invention, or of a composition according to the invention, leaving said composition in contact with the hair and / or scalp, and optionally rinsing the hair and scalp.
[0095] The following examples are intended to illustrate the invention without limiting its scope. They are given as non-limiting examples. EXAMPLES
[0096] Preparation of the extract used in the present invention Example 1: Reflux extraction with ethanol 90 2.5 kilograms of dried and ground Lespedeza capitata aerial parts are extracted with 25 liters of a 90:10 (v / v) ethanol / water mixture under stirring in a reactor for 1 hour. The extract is then filtered through K900 and the solvent is evaporated to obtain 250 grams of green powder with a mass yield of 10%. The resulting dry extract contains 26% polyphenols represented by epicatechin.
[0097] Example 2: Reflux extraction with ethyl acetate 100 grams of dried and ground aerial parts of Lespedeza capitata are extracted with 1 liter of ethyl acetate under stirring in a reactor for 1 hour. The extract is then filtered through K900 and the solvent is evaporated to obtain 2 grams of green paste with a mass yield of 2%. The resulting dry extract contains 3% polyphenols represented by epicatechin.
[0098] Example 3: Extraction with 30% ethanol at ambient temperature 20 kilograms of dried and ground Lespedeza capitata aerial parts are extracted with 350 liters of a 30:70 (v / v) ethanol / water mixture in a reactor for 12 hours under stirring at ambient temperature. The extract is then filtered through K900 and the solvent is evaporated to obtain 3.4 grams of brown powder with a mass yield of 17%. The resulting dry extract contains 36% polyphenols represented by epicatechin.
[0099] Example 4: Ultrasound-assisted extraction with ethanol 90 followed by decolorization with activated carbon 26 grams of dried and ground aerial parts of Lespedeza capitata are contacted with 260 milliliters of a 90:10 (v / v) ethanol / water mixture, then extracted under the action of ultrasound (20 kHz) at 100% amplitude for 1 min 3 times. After filtration with K900, the extract is concentrated and decolorized with activated charcoal (0.2% w / v). After filtration, the solvent is evaporated to obtain 1.5 grams of brown powder with a mass yield of 6%. The resulting dry extract contains 25% polyphenols represented by epicatechin.
[0100] Example 5: Reflux extraction with ethanol 90 and decolorization with activated carbon 280 grams of dried and ground aerial parts of Lespedeza capitata are extracted with 2800 milliliters of a 90:10 (v / v) ethanol / water mixture under stirring in a reactor for 1 hour. After filtration through K900, the extract is concentrated and decolorized with activated charcoal (0.2% w / v). After filtration, the solvent is evaporated to obtain 25 grams of extract in the form of a brown powder, with a mass yield of 9%. The extract obtained contains 25% polyphenols, represented by epicatechin.
[0101] Example 6: Reflux extraction with ethanol 90 followed by decolorization with activated carbon and entrapment on a carrier 2.5 kilograms of dried and ground aerial parts of Lespedeza capitata are extracted with 25 liters of a 90:10 (v / v) ethanol / water mixture under stirring in a reactor for 1 hour. After filtration through K900, the extract is concentrated and decolorized with activated charcoal (0.2% w / v). After filtration, the extract is dried in 1,2-pentanediol to obtain 46 grams of extract in the form of a dark viscous liquid. The extract obtained contains 50% of 1,2-pentanediol and 12% of polyphenols represented by epicatechin.
[0102] Example 7: Reflux extraction with 90% ethanol 100 grams of dried and ground Lespedeza capitata leaves are extracted with 1 liter of a 90:10 (v / v) ethanol / water mixture at reflux for 1 hour in a reactor with stirring. The extract is then filtered through K900 and the solvent is evaporated to obtain 17 grams of a green powder with a mass yield of 17%. The resulting dry extract contains 28% polyphenols represented by epicatechin.
[0103] Pharmacological evaluation Example 8: Inhibition of synthesis and release of DKK1 by dermal papilla cells by extracts of the aerial parts of Lespedeza capitata The present study aims to evaluate the effect of the extract according to the invention on the production and secretion of DKK1 by dermal papilla cells of human hair follicles, as well as the dermatological and cosmetic value of this extract as a hair loss prevention agent.DKK1 has been shown to be a key factor in androgenetic alopecia (see Kwack et al, BMB Reports, Volume 43, Issue 10, 2010, p. 688-692).
[0104] Experiments were performed on human hair follicle dermal papilla cells originating from three different donors.
[0105] These cells were seeded in 96-well plates and cultured for 24 hours in standard culture medium. The medium was then replaced with test medium containing or not containing the test compound (control condition). Lespedeza capitata is an extract prepared according to Example 5 of the present invention, and this extract was tested at two concentrations, 3 μg / ml and 10 μg / ml, which is a dried extract diluted in DMSO. After 24 hours, the culture supernatant was collected and stored at -80°C.
[0106] DKK1 protein was quantified by Luminex (kit reference: HBNMAG-51K, Millipore) according to the manufacturer's instructions.
[0107] Raw data were analyzed using Microsoft Excel and Prism software. Statistical analysis was performed by between-group comparison using ANOVA followed by Dunnett's test.
[0108] result Table 1 below shows DKK1 expression and its inhibition percentage in the presence or absence of Lespedeza capitata.
[0109] [Table 1]
[0110] Human hair follicle dermal papilla cells naturally secrete DKK1 at around 150 pg / ml. When these cells were treated with Lespedeza capitata extract, the expression of this protein was significantly decreased in a concentration-dependent manner from a concentration of 3 μg / ml. In the presence of 10 μg / ml of Lespedeza capitata extract, the decrease in DKK1 reached 72%.
[0111] Thus, the inventors have demonstrated that lespedeza extract has inhibitory activity against the DKK1 target.
[0112] This extract therefore has noteworthy activity with regard to its use as a drug in the prevention and / or treatment of hair loss.
[0113] Example 9: Inhibition of the synthesis of 5α-reductase by dermal papilla cells by extracts of the aerial parts of Lespedeza capitata The present study aims to evaluate the effect of the extract according to the invention on 5α-reductase activity in dermal papilla cells in order to evaluate the value of this extract in the field of prevention of hair loss and / or scalp seborrhea.
[0114] The experiments were carried out on human hair follicle dermal papilla cells originating from two different donors. These cells were seeded in 24-well plates (150,000 cells / well) and cultured for 24 hours in standard culture medium. The medium was then replaced for 24 hours with the test medium containing or not containing the test compound (control condition) or with the reference product (finasteride 10 μM). The Lespedeza capitata extract was an extract prepared according to Example 5 of the present invention, this extract was tested at two concentrations, 30 μg / ml and 100 μg / ml, that is, a dried extract diluted in DMSO. These cells were then cultured in a 24-well plate (150,000 cells / well) in standard culture medium. The medium was then replaced for 24 hours with the test medium containing or not containing the test compound (control condition) or with the reference product (finasteride 10 μM). The Lespedeza capitata extract was an extract prepared according to Example 5 of the present invention, this extract was tested at two concentrations, 30 μg / ml and 100 μg / ml, that is, a dried extract diluted in DMSO. 14 The cells are treated with medium containing testosterone and with or without the test compound for 24 hours, and then the culture supernatant is collected for analysis of testosterone metabolism.
[0115] The steroid molecules in the supernatant are extracted with a chloroform / methanol mixture. The organic phase is collected and DHT is separated by thin-layer chromatography using a solvent system containing dichloromethane, ethyl acetate and methanol. This chromatography is then autoradiographed and the converted testosterone is evaluated by densitometric analysis. The raw data are analyzed with Microsoft Excel. Statistical analysis is performed by group comparison using repeated measures ANOVA followed by Dunnett's test.
[0116] In this study, the DHT / testosterone ratio is chosen to represent the activity of the 5α-reductase enzyme. If this ratio is reduced by the addition of a compound, the compound is considered to be a 5α-reductase inhibitor. To be sure that the compound is truly specific for this enzyme, it is important to confirm a reduction in the 5α-androstane-3α,17β-diol / testosterone ratio and the androstenedione / testosterone ratio, as well as an increase in the 4-androstene-3,17-dione / testosterone ratio.
[0117] result Table 2 below shows the 5α-reductase activity (DHT / testosterone ratio) after 24h + 24h incubation with a reference compound (finasteride) and with Lespedeza capitata extract.
[0118] [Table 2]
[0119] Treatment of human hair follicle dermal papilla cells with finasteride shows a very strong reduction in the conversion of testosterone to DHT (reduced DHT / testosterone ratio). These results were expected and allow validation of the study.
[0120] In the presence of Lespedeza capitata extract, the DHT / testosterone ratio was decreased in a concentration-dependent manner, and this decrease (reaching 60%) was statistically significant at a Lespedeza capitata concentration of 100 μg / ml. Although the activity at 30 μg / ml was not considered statistically significant, it is still suggestive.
[0121] Thus, the present inventors have clearly demonstrated that lespedeza extract has inhibitory activity against 5α-reductase.
[0122] Thus, this Lespedeza capitata extract exhibits noteworthy activity with regard to its use as a drug in the prevention and / or treatment of skin and hair disorders, in particular hair loss and / or scalp seborrhea and related disorders.
[0123] Example 10: Inhibition of metabolic activity and / or proliferation of dermal papilla cells by extracts of the aerial parts of Lespedeza capitata The dermal papilla is present at the base of the hair follicle, anchored deep in the skin tissue. It has long been known that dermal papilla cells play an important role in hair follicle growth. Rich in blood vessels, the dermal papilla provides nutrients to the hair and provides the molecular information required for epithelial cell proliferation and differentiation to produce new hair every cycle. Studies have shown that there is a correlation between the size of the dermal papilla and the number of cells in the dermal papilla and also the size of the hair shaft in healthy human hair follicles and in lesion-induced beard regeneration models in rat experiments. This correlation is maintained with progressive hair loss, where the size of the hair follicle and hair shaft decreases continuously with the hair growth cycle. Furthermore, although the increase in the number of cells of the dermal papilla in the hair follicle may occur in part by recruitment of new cells to the dermal papilla, proliferation of dermal papilla cells also contributes to this expansion.
[0124] The present study aims to evaluate the effect of an extract according to the invention on the metabolic activity and / or proliferation of dermal papilla cells in order to evaluate the value of this extract in the field of hair loss prevention.
[0125] Experiments were performed on human hair follicle dermal papilla cells originating from three different donors.
[0126] These cells were seeded in 96-well plates and cultured for 24 hours in standard culture medium. The medium is then replaced with the test medium (Follicle Dermal Papilla Cell Basal) (HFDPC) medium, Ref C-26500 from Promocell) containing or not containing the test compound (control condition). A group of the same medium supplemented with 5% supplement medium (Follicle Dermal Papilla Cell Growth Medium SupplementPack, Ref C-39620, Promocell) serves as the positive control. The Lespedeza capitata extract is an extract prepared according to Example 2 of the present invention, this extract is tested at two concentrations, 3 μg / ml and 10 μg / ml, which is a dried extract diluted in DMSO. After 72 hours, the culture supernatant is collected and stored at -80°C.
[0127] Cell metabolic activity and proliferation are assessed by a colorimetric method, a soluble tetrazolium salt (WIST-1), which is light red in color and turns red when reduced to formazan (test sold by Takara Clontech, catalog number MK400). Raw data are analyzed using Microsoft Excel. Statistical analysis is performed by comparison between groups using repeated measures ANOVA followed by Dunnett's test.
[0128] result Table 3 shows the results of the Lespedeza extract on metabolic activity and cell proliferation.
[0129] [Table 3]
[0130] Treatment of dermal papilla cells with the medium containing the additive induces a significant activation of cell proliferation and / or metabolic activity. This result confirms the validity of this model. 3 μg / ml of Lespedeza capitata extract induces a statistically significant increase in cell proliferation and / or metabolic activity. This activation does not reach significance at 10 μg / ml of Lespedeza capitata, probably due to the high variability of the results, but it still suggests at least an effect of the extract.
[0131] Thus, the inventors have clearly demonstrated that the Lespedeza extract has a stimulating activity on cell proliferation and / or metabolic activity, and thus this Lespedeza capitata extract has a notable activity with regard to its use in promoting hair growth by strengthening and stimulating the hair life cycle and by promoting hair regeneration.
[0132] Example 11: Evaluation of Lespedeza capitata aerial parts for human JAK1, JAK2 and JAK3 inhibition JAK-STAT is a signaling pathway for transduction that regulates growth, survival, differentiation and resistance to pathogens. This pathway mediates the effects of cytokines, interferons and growth factors. In mammals, the JAK family consists of four members: JAK1, JAK2, JAK3 and TYK2. Studies performed in mouse hair follicles have shown that the JAK-STAT pathway is dynamically regulated in the hair cycle, with the JAK-STAT pathway being activated during catagen and telogen and suppressed at the onset of anagen. Furthermore, in mice, topical treatment with JAK-STAT pathway inhibitors, including tofacitinib (JAK1 / 3>JAK2>TYK2) and ruxolitinib (JAK1 / 2>TYK2>JAK3) during telogen phase was shown to result in a rapid return to the onset of anagen (Harel et al., 2015 Sci. Adv.1, e1500973). This same study also shows that inhibition of JAK-STAT in human hair follicles increases hair growth ex vivo. These data suggest that the JAK-STAT signaling pathway may be a new target for stimulating hair growth.
[0133] The aim of this example is to evaluate whether the extract according to the invention is capable of inhibiting the JAK-STAT signaling pathway, by assessing human recombinant JAK1, JAK2 or JAK3 proteins.
[0134] method Lespedeza capitata extract is an extract prepared according to Example 5 of the present invention. This extract is diluted in DMSO and tested at various concentrations (0.1-1000 μg / ml). Positive controls (tofacitinib and ruxolitinib) are also evaluated in this study.
[0135] The samples are incubated with human recombinant JAK1, JAK2 or JAK3 proteins in reaction buffer (Tris / HCl for JAK1, MOPS (3-morpholino-1-propanesulfonic acid) for JAK2 and JAK3), EDTA and the specific peptide substrate. The phosphorylation reaction is then started by the addition of a mixture of magnesium acetate and radiolabeled ATP (45 μM for JAK1 and JAK2 and 10 μM for JAK3). After 40 min of incubation at ambient temperature, the reaction is stopped by the addition of phosphoric acid. The small molecules, including the labeled ATP, are eluted by washing four times with phosphoric acid and once with methanol. Finally, the radioactivity of the specific phosphorylated substrate is measured. The compounds are tested in three independent experiments, with two replicates for each experiment.
[0136] IC of each recombinant JAK1, JAK2, and JAK3 protein by test sample 50 Values (μg / ml) are shown in Table 4 below.
[0137] [Table 4]
[0138] The results obtained with the reference compounds (ruxolitinib and tofacitinib) are similar to those expected. Indeed, these two compounds strongly inhibit JAK-STAT activity (maximum inhibition 97%-100% with extremely low IC of around 1 nanogram per milliliter). 50 Ruxolitinib has greater affinity for JAK1 or JAK2 than for JAK3. Tofacitinib has greater affinity for JAK1 or JAK3 than for JAK2. These expected results validate the study.
[0139] The extract of the aerial parts of Lespedeza capitata was found to be effective in preventing the development of I.C. 50 A value of 24.8 μg / ml showed strong inhibition of JAK1 (maximum inhibition 100%), and a somewhat high IC 50 The IC value of 146.5 μg / ml showed strong inhibition of JAK2 (maximum inhibition 100%), and the IC 50 A value of 3.9 μg / ml indicates strong inhibition of JAK3 (maximum inhibition 100%).
[0140] The present study demonstrates that Lespedeza capitata extract induces inhibition of tyrosine kinase activity (with greater affinity for JAK3), revealing notable pharmacological activity for promoting hair growth.
[0141] Example 12: Confirmation of JAK-STAT pathway inhibitory activity of the extract of Lespedeza capitata aerial parts at the cellular level The purpose of this example is to confirm the inhibitory activity of Lespedeza capitata extract on the JAK-STAT signaling pathway in a cell model, namely, follicular keratinocytes of the outer epithelial sheath of the hair follicle (the outer root sheath (ORS) model). In this model, the interleukin IL-6 is used to activate the JAK1 / 2-STAT3 pathway by activating the IL-6 receptor and the GP130 receptor, both of which are expressed in this hair follicle epithelial sheath. Il-6 is a cytokine that acts as a hair growth cycle inhibitor. Its overexpression in a transgenic mouse model results in delayed hair growth. Moreover, in androgenetic alopecia, IL-6 appears to be overexpressed in dermal papilla cells under the influence of androgens (Kwack et al., 2012, J Invest Dermatology 132(1): 43-9). It has also been reported that IL-6 retards hair follicle growth in humans.
[0142] method The study is carried out on follicular keratinocytes of the outer epithelial sheath of the hair follicle (Outer Root Sheath (ORS) model). Keratinocytes are cultured in the appropriate medium (CnT-PR, CellNTech) in 96-well plates. After 24 hours, cells are washed with alkaline phosphate buffer (PBS) and the medium is replaced with CnT-PR-H (standard maintenance medium for primary human keratinocytes). After 48 hours, cells are treated for 1 hour with the test compounds (Lespedeza capitata extract at 30 and 100 μg / ml diluted in DMSO) and with the reference compounds (ruxolitinib and tofacitinib at 5 μM, both diluted in DMSO). The Lespedeza capitata tested is the extract prepared according to Example 5 of the present invention. Stimulation with IL-6 is then carried out at 100 ng / ml for 15 minutes.
[0143] All conditions are tested on cells from n=3 different donors. Lespedeza capitata extracts are tested in n=3 different experiments, control conditions, stimuli and reference compounds in n=6 experiments. For each experiment, data are obtained in triplicates.
[0144] JAK activity is evaluated by assessing the degree of phosphorylation of STAT3 protein. Statistical analysis is performed by parametric tests after checking normality and homogeneity of variance, otherwise non-parametric tests are selected.
[0145] result The results are summarized in Table 5 below.
[0146] [Table 5]
[0147] Treatment of keratinocytes with IL-6 induces a significant increase in the degree of phosphorylation of STAT3. This increase reaches 16% and is statistically significant (p<0.05). The reference compounds (ruxolitinib and tofacitinib tested at 5 μM) significantly reduce the degree of phosphorylation of STAT3 (85% and 104%, respectively, p<0.05 for ruxolitinib and p<0.01 for tofacitinib). These expected results confirm the validity of the study.
[0148] Lespedeza capitata extract significantly (p<0.01 for both concentrations) and highly significantly inhibited the level of STAT3 phosphorylation induced by IL-6 stimulation at both concentrations tested.
[0149] Thus, the inventors demonstrate the value of an extract of the aerial parts of Lespedeza capitata in promoting hair regrowth.
Claims
1. A composition comprising a hydroalcoholically extracted Lespedeza capitata extract for the treatment and / or prevention of at least one skin and hair disorder, characterized in that the at least one skin and hair disorder is selected from alopecia, scalp seborrhea and combinations thereof.
2. 2. The composition according to claim 1, wherein the extract of Lespedeza capitata is selected from a hydroalcoholic extract of the roots of Lespedeza capitata and a hydroalcoholic extract of the aerial parts of Lespedeza capitata.
3. 3. The composition according to claim 1 or 2, wherein the Lespedeza capitata extract is a hydroethanolic Lespedeza capitata extract.
4. 4. The composition according to any one of claims 1 to 3, wherein the Lespedeza capitata extract comprises 10 to 40% by weight of total polyphenols based on the weight of the dry extract.
5. The composition according to any one of claims 1 to 4, wherein the alopecia is selected from the group consisting of androgenetic alopecia, reactive alopecia, postmenopausal alopecia and alopecia areata.
6. A composition according to any one of claims 1 to 5, which is a cosmetic or dermatological composition, comprising as active ingredient an extract of Lespedeza capitata as defined in any one of claims 1 to 5 and at least one cosmetically or dermatologically acceptable excipient.
7. 7. The composition according to claim 6, comprising 0.0001 to 2% by weight of Lespedeza capitata extract, by weight of dry extract relative to the total weight of the composition.
8. The composition of claim 6, comprising 0.001 to 1% by weight of Lespedeza capitata extract, based on the weight of the dry extract relative to the total weight of the composition.
9. A composition according to any one of claims 6 to 8, which is in a form suitable for topical administration to the scalp and / or hair.
10. 8. The composition according to claim 6 or 7, which is in a form suitable for oral administration.
Citation Information
Patent Citations
5alpha-reductase inhibitor
JP1989096126A
Composition including lespedeza bicolor extract for preventing hair loss or promoting hair growth
KR1020130091406A
Compositions comprising lespedeza plant extract
WO2018127612A2
